KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Preferred Shares (2017 - 2021)

Arbutus Biopharma's Preferred Shares history spans 5 years, with the latest figure at $155.9 million for Q2 2021.

  • For Q2 2021, Preferred Shares rose 8.81% year-over-year to $155.9 million; the TTM value through Jun 2021 reached $155.9 million, up 8.81%, while the annual FY2020 figure was $149.4 million, 8.83% up from the prior year.
  • Preferred Shares for Q2 2021 was $155.9 million at Arbutus Biopharma, up from $152.6 million in the prior quarter.
  • Across five years, Preferred Shares topped out at $155.9 million in Q2 2021 and bottomed at $49.8 million in Q4 2017.
  • The 5-year median for Preferred Shares is $135.8 million (2019), against an average of $130.9 million.
  • The largest annual shift saw Preferred Shares increased 8.86% in 2020 before it rose 8.81% in 2021.
  • A 5-year view of Preferred Shares shows it stood at $49.8 million in 2017, then soared by 148.07% to $123.5 million in 2018, then grew by 11.17% to $137.3 million in 2019, then rose by 8.83% to $149.4 million in 2020, then grew by 4.34% to $155.9 million in 2021.
  • Per Business Quant, the three most recent readings for ABUS's Preferred Shares are $155.9 million (Q2 2021), $152.6 million (Q1 2021), and $149.4 million (Q4 2020).